本文選題：新輔助化療　切入點(diǎn)：XELOX　出處：《皖南醫(yī)學(xué)院》2017年碩士論文

【摘要】：目的:系統(tǒng)性評(píng)價(jià)XELOX方案新輔助化療對(duì)進(jìn)展期胃癌患者的療效。方法:計(jì)算機(jī)全面檢索:Medline、Cochrane library、CNKI、EMbase、VIP、相關(guān)期刊論文(CJFD)、中國(guó)生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫(kù)(CBMdisc)等中外數(shù)據(jù)庫(kù)。檢索日期從1989年1月至今的關(guān)于進(jìn)展期胃癌患者采用XELOX方案術(shù)前新輔助化療對(duì)比術(shù)前不接受任何形式的輔助治療直接行手術(shù)治療+術(shù)后化療的所有文章。對(duì)納入的文章使用相應(yīng)的方法進(jìn)行質(zhì)量評(píng)定,納入符合納入標(biāo)準(zhǔn)的高質(zhì)量的文章,所收集的數(shù)據(jù)采用Review Manager5.2進(jìn)行Meta分析。結(jié)果:本研究納入了11篇臨床試驗(yàn),8篇隨機(jī)對(duì)照研究,3篇回顧性對(duì)照研究,一共有870例患者入選本研究,其中試驗(yàn)組(術(shù)前行XELOX新輔助化療組)446例,對(duì)照組(術(shù)前不接受任何形式的輔助治療直接行手術(shù)治療+術(shù)后化療組)424例。Meta分析的結(jié)果顯示:術(shù)前行XELOX方案新輔助化療的患者同單純手術(shù)+術(shù)后化療的患者相比總手術(shù)率R1更高(OR值為8.28,95%CI為3.58-19.15,P0.00001),根治性手術(shù)切除率R0更高(OR值為3.75,95%CI為2.67-5.28,P0.00001),1年生存率更高(OR值為2.79,95%CI為1.55-5.02,P=0.00060.05),2年生存率更高(OR值為2.78,95%CI為1.36-5.68,P=0.0050.05),3年生存率更高(OR值為2.57,95%CI為1.28-5.17,P=0.0080.05)。結(jié)論:1.術(shù)前行XELOX方案新輔助化療的進(jìn)展期胃癌患者較單純手術(shù)+術(shù)后化療的患者總手術(shù)率R1和根治性切除率R0更高,差異均有統(tǒng)計(jì)學(xué)意義。2.術(shù)前行XELOX方案新輔助化療的進(jìn)展期胃癌患者較單純手術(shù)+術(shù)后化療的患者1、2、3年生存率更高,差異均有統(tǒng)計(jì)學(xué)意義。XELOX方案新輔助化療在臨床上值得推薦。
[Abstract]:Objective: to systematically evaluate the efficacy of neoadjuvant chemotherapy with XELOX regimen in the treatment of advanced gastric cancer. Methods: the Chinese and foreign databases, such as the Chinese Journal Full-text Database, the Chinese Biomedical Literature Database and the Chinese Biomedical Literature Database, were searched by computer. All articles dated from January 1989 to present concerning the use of XELOX regimen for preoperative neoadjuvant chemotherapy in patients with advanced gastric cancer as opposed to any form of adjuvant therapy before operation, direct surgical treatment and postoperative chemotherapy. The article uses the corresponding method to evaluate the quality. The collected data were analyzed by Review Manager5.2 for Meta analysis. Results: 11 clinical trials, 8 randomized controlled trials and 3 retrospective controlled trials were included in this study. A total of 870 patients were enrolled in the study, including 446 patients in the experimental group (XELOX neoadjuvant chemotherapy before operation), The results of Meta-analysis in the control group (without any form of adjuvant therapy before operation and direct postoperative chemotherapy) showed that the patients who received neoadjuvant chemotherapy with XELOX regimen before operation were compared with those who received chemotherapy after surgery alone. The OR value higher than the total operation rate R1 was 8.28 鹵95CI 3.58-19.15P0.00001, the radical resection rate R0 higher OR = 3.75-5.28P0.00001C, the one-year survival rate higher OR = 2.7995CI 1.55-5.02P0.00060.05U, the 2-year survival rate higher OR = 2.78-5.68P0.0050.05, the 3-year survival rate higher OR = 2.575.95CI = 1.28-5.175.175.02P0.005.Conclusion: the higher OR value is 1.36-5.68P0.0050.05, and the higher 3-year survival rate is 2.5795 CI = 1.28-5.175.175.02P = 0.00060.05. Conclusion: the higher OR value is 1.36-5.68P0.0050.05, and the higher OR value is 2.5795 CI = 1.28-5.175.175.02P 0.00060.05, 2.78-5.68P0.0050.05. Patients with advanced gastric cancer who received neoadjuvant chemotherapy with XELOX regimen before operation were more likely to have higher total operation rate (R1) and radical resection rate (R0) than those with postoperative chemotherapy alone. The 3-year survival rate of patients with advanced gastric cancer undergoing neoadjuvant chemotherapy with XELOX regimen before operation was higher than that of patients with postoperative chemotherapy alone. The difference was statistically significant. The neoadjuvant chemotherapy of Xerox regimen was worth recommending clinically.
【學(xué)位授予單位】：皖南醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：R735.2

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 崔勇;張榮香;王福立;魏本尊;張建東;;新輔助化療聯(lián)合術(shù)后同步放化療治療Ⅲ期胃癌的療效分析[J];中國(guó)腫瘤臨床;2016年17期

2 李小寶;訾永宏;劉勇峰;李曉勇;梅樂園;車向明;;不同術(shù)式治療的T_1～T_4期胃癌患者5年生存率分析[J];山東醫(yī)藥;2016年27期

3 尤昊;趙旭輝;魏忠;戴寅;謝釗;;新輔助化療在進(jìn)展期胃癌中的臨床應(yīng)用[J];安徽醫(yī)學(xué);2015年12期

4 Alberto Biondi;Maria C Lirosi;Domenico D'Ugo;Valeria Fico;Riccardo Ricci;Francesco Santullo;Antonia Rizzuto;Ferdinando CM Cananzi;Roberto Persiani;;Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives[J];World Journal of Gastrointestinal Oncology;2015年12期

5 魏俊;龔光偉;肖莎;;XELOX方案術(shù)前化療對(duì)進(jìn)展期胃癌手術(shù)治療效果的影響[J];現(xiàn)代診斷與治療;2015年17期

6 徐迅;張長(zhǎng)樂;;奧沙利鉑聯(lián)合卡培他濱新輔助化療方案在ⅡB～ⅢC期胃癌中的應(yīng)用[J];安徽醫(yī)藥;2015年05期

7 胡佳楠;徐益元;;奧沙利鉑聯(lián)合卡培他濱新輔助化療對(duì)進(jìn)展期胃癌的療效觀察[J];浙江臨床醫(yī)學(xué);2014年02期

8 胡祥;;胃癌根治術(shù)式選擇與原則[J];中華普外科手術(shù)學(xué)雜志(電子版);2013年01期

9 朱正綱;;進(jìn)展期胃癌外科綜合治療的發(fā)展趨勢(shì)[J];中華胃腸外科雜志;2012年02期

10 黎柏峰;王勁;葉亮;張勝祖;;奧沙利鉑聯(lián)合卡培他濱治療進(jìn)展期胃癌的臨床研究[J];中國(guó)醫(yī)藥指南;2011年08期

相關(guān)碩士學(xué)位論文 前1條

1 田園;XELOX方案術(shù)前化療對(duì)進(jìn)展期胃癌治療作用的研究[D];河北醫(yī)科大學(xué);2013年

，

本文編號(hào)：1671095